Literature DB >> 8662098

Somatostatin-receptor scintigraphy in Graves' orbitopathy.

P T Postema, D J Kwekkeboom, P M van Hagen, E P Krenning.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8662098     DOI： 10.1007/bf00834521

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN： 0340-6997


× No keyword cloud information.
  15 in total

1.  Ocular changes in Graves' disease. A long-term follow-up study.

Authors:  I B HALES; F F RUNDLE
Journal:  Q J Med       Date:  1960-01

2.  Somatostatin analogue scintigraphy of malignant lymphomas.

Authors:  P M Vanhagen; E P Krenning; J C Reubi; A H Mulder; W H Bakker; H Y Oei; B Löwenberg; S W Lamberts
Journal:  Br J Haematol       Date:  1993-01       Impact factor: 6.998

3.  Somatostatin-receptor imaging in the localization of endocrine tumors.

Authors:  S W Lamberts; W H Bakker; J C Reubi; E P Krenning
Journal:  N Engl J Med       Date:  1990-11-01       Impact factor: 91.245

Review 4.  Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Authors:  E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi
Journal:  Eur J Nucl Med       Date:  1993-08

5.  Indium-111-pentetreotide scintigraphy in Graves' ophthalmopathy.

Authors:  G Kahaly; M Diaz; K Hahn; J Beyer; A Bockisch
Journal:  J Nucl Med       Date:  1995-04       Impact factor: 10.057

6.  Somatostatin analogue scintigraphy in granulomatous diseases.

Authors:  P M Vanhagen; E P Krenning; J C Reubi; D J Kwekkeboom; W H Bakker; A H Mulder; I Laissue; H C Hoogstede; S W Lamberts
Journal:  Eur J Nucl Med       Date:  1994-06

7.  Somatostatin receptor imaging. The presence of somatostatin receptors in rheumatoid arthritis.

Authors:  P M Vanhagen; H M Markusse; S W Lamberts; D J Kwekkeboom; J C Reubi; E P Krenning
Journal:  Arthritis Rheum       Date:  1994-10

8.  Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach.

Authors:  M P Mourits; L Koornneef; W M Wiersinga; M F Prummel; A Berghout; R van der Gaag
Journal:  Br J Ophthalmol       Date:  1989-08       Impact factor: 4.638

9.  [111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity?

Authors:  P T Postema; E P Krenning; R Wijngaarde; P P Kooy; H Y Oei; W A van den Bosch; J C Reubi; W M Wiersinga; H Hooijkaas; T van der Loos
Journal:  J Clin Endocrinol Metab       Date:  1994-12       Impact factor: 5.958

10.  Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone.

Authors:  L Bartalena; C Marcocci; L Chiovato; M Laddaga; G Lepri; D Andreani; G Cavallacci; L Baschieri; A Pinchera
Journal:  J Clin Endocrinol Metab       Date:  1983-06       Impact factor: 5.958
View more
  3 in total

1.  Locally produced insulin-like growth factor-1 by orbital fibroblasts as implicative pathogenic factor rather than systemically circulated IGF-1 for patients with thyroid-associated ophthalmopathy.

Authors:  Delu Song; Renyan Wang; Yong Zhong; Weiye Li; Hui Li; Fangtian Dong
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-12-09       Impact factor: 3.117

2.  [Octreotide scintigraphy for the diagnosis of active Graves' ophthalmopathy].

Authors:  N Ardjomand; G Esche; P Fellner; S Lindner; M Panzitt; R Aigner; A Langmann
Journal:  Ophthalmologe       Date:  2003-12       Impact factor: 1.059

3.  Somatostatin receptor imaging by SPECT and PET in patients with chronic inflammatory disorders: a systematic review.

Authors:  Luz Kelly Anzola; Andor W J M Glaudemans; Rudi A J O Dierckx; F Andres Martinez; Sergio Moreno; Alberto Signore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-28       Impact factor: 9.236
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.